Illumina is a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. The company's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company was founded in 1998 and is based in San Diego, California.
ILMN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for ILMN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Illumina Inc ranked in the 29th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Illumina Inc ended up being:
The company's debt burden, as measured by earnings divided by interest payments, is 21.05; that's higher than 86.41% of US stocks in the Healthcare sector that have positive free cash flow.
The business' balance sheet suggests that 4% of the company's capital is sourced from debt; this is greater than only 12.64% of the free cash flow producing stocks we're observing.
ILMN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 45.87% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ILMN, try CPIX, JNJ, LMAT, ZTS, and HAPP.
A report by The Insight Partner's on the Gene Expression Market discusses the growth of the market in great detail. It discusses thoroughly all factors promoting and deterring the market. The report also focuses on the competitive dynamics in the
The numerous recent developments, products launches, research, joint ventures, mergers and acquisitions in the Function Driven Metagenomics market which is changing the face healthcare industry.We at Data Bridge Market Research understand what is important in the Function Driven
Deals and Financings Illumina (ILMN) will acquire GRAIL (GRAL), an Illumina spin-out that is developing an early screening test for multiple forms of cancer, for $8 billion in cash and stock (see story). In 2017, GRAIL bought Cirina, a Hong Kong-San Francisco liquid biopsy company cofounded by Dr. Dennis Lo,...
ChinaBio Today on Seeking Alpha | September 28, 2020
SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the third quarter 2020 following the close of market on Thursday, October 29, 2020. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details